International Review of Psychiatry
May 23, 2024
Rebecca Ehrenkranz, Manish Agrawal, J. Kim Penberthy et al.
5 citations
Prolonged Grief Disorder (PGD) is distinct from yet related to non-pathologic grief, depression, addiction, and Post-Traumatic Stress Disorder (PTSD) with a prevalence of up to 10% in bereaved populations. Hallmarks of PGD include functional impairment a year or more post-bereavement and intense yearning for the deceased. Current treatments for PGD are typically psychological rather than...
Trials
May 21, 2024
Chiranth Bhagavan, Paul Glue, Will Evans et al.
7 citations
Symptoms of anxiety and depression are common in patients with terminal illness and multiple challenges exist with timely and effective care in this population. Several centres have reported that one dose of the serotonergic psychedelic psilocybin, combined with therapeutic support, improves these symptoms for up to 6 months in this patient group. Drawing upon related therapeutic mechanisms,...
The British Journal of Psychiatry
May 20, 2024
David Nutt, Ilana B Crome, Allan H. Young
18 citations
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for treatment-resistant depression and post-traumatic stress disorder respectively. This feature explores the reasons for these developments, the opportunities and challenges they provide to psychiatry communities and how along with health systems these...
Neuropsychopharmacology
May 13, 2024
Conor H. Murray
MDMA-assisted psychotherapy has emerged as a potential treatment for psychiatric illnesses, with findings from clinical trials in the last decade demonstrating safety and efficacy in the treatment of posttraumatic stress disorder (PTSD), among other psychiatric indications. Earlier this year (2024), the Food and Drug Administration in the United States granted priority review for a new drug...
Drug and Alcohol Review
May 1, 2024
Nicole D. Fitzgerald, Joseph J Palamar
5 citations
Ecstasy (3,4-methylenedioxymethamphetamine [MDMA]) is a drug commonly used by people who attend electronic dance music (EDM) events at nightclubs and dance festivals. Drug checking has gained popularity in recent years to test for adulterants, but epidemiology studies are needed to estimate potential shifts in prevalence of drug checking to further inform harm reduction efforts. Adults entering...
The International Journal of Neuropsychopharmacology
May 1, 2024
Gessica Piras, Cristina Cadoni, Francesca Caria et al.
3 citations
The proliferation of novel psychoactive substances (NPS) in the drug market raises concerns about uncertainty on their pharmacological profile and the health hazard linked to their use. Within the category of synthetic stimulant NPS, the phenethylamine 2-Cl-4,5-methylenedioxymethamphetamine (2-Cl-4,5-MDMA) has been linked to severe intoxication requiring hospitalization. Thereby, the...
Journal of Chromatography B
May 1, 2024
Dino Luethi, Deborah Rudin, Isabelle Straumann et al.
6 citations
3,4-Methylenedioxymethamphetamine (MDMA) is an entactogen with therapeutic potential. The two enantiomers of MDMA differ regarding their pharmacokinetics and pharmacodynamics but the chiral pharmacology of MDMA needs further study in clinical trials. Here, an achiral and an enantioselective high performance liquid chromatography-tandem mass spectrometry method for the quantification of MDMA and...
Læknablaðið
May 1, 2024
Helga Thorarinsdottir, Berglind Gudmundsdottir, Engilbert Sigurðsson
1 citation
MDMA is a potential novel treatment for post-traumatic stress disorder (PTSD). Our goal is to review current knowledge on MDMA and its use in MDMA-assisted psychotherapy for PTSD. Literature searches were done on PubMed, Web of Science and Google Scholar and references reviewed in identified articles. MDMA-assisted therapy for PTSD usually consists of a few preparatory sessions before two or...
Cureus
May 1, 2024
Melissa N Litenski, Aoife B O'Reardon, Nicole Pabon et al.
1 citation
MDMA (3,4-methylenedioxymethamphetamine), also known as Ecstasy, is a synthetic amphetamine with hallucinogenic and stimulant properties, which has become increasingly favored as a substance for recreational use. Despite its deceptive reputation as "safe," chronic MDMA use is associated with neuropsychiatric complications, including psychosis. We describe a case of a 23-year-old woman with...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
May 1, 2024
Mihai Avram, Felix Müller, Katrin H. Preller et al.
13 citations
While the exploration of serotonergic psychedelics as psychiatric medicines deepens, so does the pressure to better understand how these compounds act on the brain. We used a double-blind, placebo-controlled, crossover design and administered lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), and d-amphetamine in 25 healthy participants. By using spectral dynamic causal...
Journal of Psychopharmacology
May 1, 2024
Arman Shafiee, Razman Arabzadeh Bahri, Mohammad Ali Rafiei et al.
21 citations
Retracted
Recent interest in the potential therapeutic effects of psychedelics has led to investigations into their influence on molecular signaling pathways within the brain. Integrated review and analysis of different studies in this field. A systematic search was conducted across international databases including Embase, Scopus, Web of Science, and PubMed from inception to 9 July 2023. Eligibility...
Science Advances
April 26, 2024
Ben Rein, Kendall Raymond, Cali Boustani et al.
37 citations
MDMA (3,4-methylenedioxymethamphetamine) is a psychoactive drug with powerful prosocial effects. While MDMA is sometimes termed an "empathogen," empirical studies have struggled to clearly demonstrate these effects or pinpoint underlying mechanisms. Here, we paired the social transfer of pain and analgesia-behavioral tests modeling empathy in mice-with region-specific neuropharmacology,...
Turkish Academic Research Review - Türk Akademik Araştırmalar Dergisi [TARR]
April 23, 2024
Merve Nur Kaptan
Ecstasy is a state of altered consciousness in which a person is in a state of trance. The person in this state experiences an introspection and returns to their essence. Such a state can also be likened to being asleep or hypnotized. But more than these states, ecstasy refers to a conventionalized state of unusualness. In other words, ecstasy can occur in societies and these moods of ecstasy...
Neuropsychopharmacology
April 23, 2024
Julia Colcott, Olivia Carter, Sally Meikle et al.
37 citations
Abstract Evidence suggests that MDMA-assisted psychotherapy (MDMA-AP) has therapeutic potential for treatment of psychiatric illness. We conducted the first comprehensive systematic review and meta-analysis of the side effects of MDMA-AP across indications. We also assessed the quality of side effects-reporting in published trials of MDMA-AP. PubMed, EMBASE, PsycINFO, MEDLINE and Cochrane...
Australian & New Zealand Journal of Psychiatry
April 16, 2024
Samuel P Hatfield, Nicollette Lr Thornton, Kayla Greenstien et al.
9 citations
Objectives: The Australian government recently rescheduled psilocybin and 3,4-methylenedioxymethamphetamine for limited clinical uses. This change has raised various regulatory concerns and challenges for the field of psychedelic-assisted therapy. To provide clarity, we aimed to comprehensively catalogue the matters relating to psychedelic-assisted therapy that are or could be regulated....
Research, Society and Development
April 11, 2024
Jéssica de Sá Azevedo, Aline da Silva Guerra
1 citation
O transtorno do espectro autista é uma condição no neurodesenvolvimento que causa déficits na interação interpessoal e na comunicação do indivíduo, podendo levar ao desenvolvimento da ansiedade social. A inexistência de um tratamento farmacológico eficaz e com efeitos colaterais reduzidos, tem atraído a atenção dos pesquisadores para o tratamento com abordagens alternativas. O...
bioRxiv : the preprint server for biology
April 11, 2024
Ana Sofia Alberto-Silva, Selina Hemmer, Hailey A. Bock et al.
preprint
3,4-Methylenedioxymethamphetamine (MDMA, ' ecstasy' ) is re-emerging in clinical settings as a candidate for the treatment of specific psychiatric disorders (e.g. post-traumatic stress disorder) in combination with psychotherapy. MDMA is a psychoactive drug, typically regarded as an empathogen or entactogen, which leads to transporter-mediated monoamine release. Despite its therapeutic...
Drug Addiction Mechanisms in the Brain
April 8, 2024
Jayalakshmi Krishnan
1 citation
3,4-methylenedioxy-methamphetamine (MDMA) is a synthetic drug very similar to hallucinogens and stimulants. This drug is also called ecstasy or molly. It produces feelings of pleasure, warmth, distorted sensory time and perception. MDMA increases the activity of serotonin, dopamine and norepinephrine in the brain. It causes various health effects such as nausea, sweating, chills, muscle...
April 2, 2024
Harman Chopra, Timothy Furnish, Monica Verduzco-Gutierrez et al.
IntroductionCoronavirus disease 2019 (COVID-19) is a highly contagious respiratory illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus was first identified in Wuhan, China in December 2019 and has since spread
Nervenheilkunde
April 1, 2024
Laura Bechtold, Dimitris Repantis
ZUSAMMENFASSUNGNeben den klassischen Psychedelika, z. B. Psilocybin, werden wieder vermehrt andere Substanzen wie 3,4-Methylendioxy-N-methylamphetamin (MDMA) erforscht. Das Entaktogen („innerlich berührend“) ist in den USA nur noch wenige Schritte von einer möglichen Zulassung zur Behandlung der posttraumatischen Belastungsstörung entfernt. Dieser Artikel soll einen Überblick über die Wirkung,...